The US Food and Drug Administration (FDA) has approved an expanded indication for AstraZeneca’s Faslodex (fulvestrant) in combination with Verzenio / abemaciclib, a CDK4/6 inhibitor, to treat advanced breast cancer.
Faslodex has been approved for use in treating women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer (MBC) with disease progression after endocrine therapy.
Go deeper with GlobalData
The drug is indicated for the treatment of oestrogen receptor-positive, locally advanced or MBC in post-menopausal women not previously treated with endocrine therapy, or with disease relapse on or after adjuvant anti-oestrogen therapy, or disease progression on anti-oestrogen therapy.
AstraZeneca Oncology Business Unit executive vice-president and head Dave Fredrickson said: “Faslodex has long been an effective monotherapy option for women with hormone receptor-positive breast cancer, which is the most common type of advanced breast cancer.
“Today’s decision builds upon the recent approval for Faslodex in the first-line advanced setting and is supported by strong evidence to use this medicine within a combination therapy for advanced breast cancer.
“Combining Faslodex with abemaciclib provides patients with another effective, non-chemotherapy option to combat this disease.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe approval is based on data obtained from the international, randomised, double-blind, placebo-controlled, multicentre, Phase III Monarch 2 trial.
The study, sponsored by Eli Lilly and Company, involved 669 women with HR+, HER2- advanced breast cancer.
The additional indication is the second FDA approval for AstraZeneca’s Faslodex in combination with a CDK4/6 inhibitor.
Last year, the therapy was licensed in the US for use with the CDK4/6 inhibitor, palbociclib, to treat women with HR+, HER2- MBC, whose cancer has progressed after endocrine therapy.
